CME Presentations

MDS


Presentations


Speakers

  • Mikkael Sekeres, MD, MS

    Mikkael Sekeres, MD, MS

    Mikkael Sekeres, MD, MS

    Professor of Medicine

    Mikkael Sekeres, MD, MS, is professor of medicine and chief of the Division of Hematology in the Department of Medicine and physician liaison for the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine in Florida. His research focuses on patients with myelodysplastic syndrome and older adults with acute myeloid leukemia, and he has been the national and international primary study investigator on several trials. Dr Sekeres is the author or co-author of over 350 manuscripts and 650 abstracts published in leading journals. He has also authored 7 books, including When Blood Breaks Down: Life Lessons from Leukemia. Dr Sekeres is chair of the medical advisory board of the Aplastic Anemia and Myelodysplastic Syndrome International Foundation.
  • Hetty Carraway, MD, MBA, FACP

    Hetty Carraway, MD, MBA, FACP

    Hetty Carraway, MD, MBA, FACP

    Director, Leukemia Program

    Hetty Caraway, MD, MBA, FACP, is associate professor of medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, vice chair of strategy and enterprise development at the Taussig Cancer Institute in the Division of Hematologic Oncology and Blood Disorders, and director of the Leukemia Program at the Cleveland Clinic in Ohio. Her research is focused on experimental therapeutics of acute leukemias and myeloproliferative diseases. Dr Carraway has co-authored numerous peer-¬reviewed publications, review articles, editorials, abstracts, and book chapters. She is nationally sought for her expertise in hematologic malignancies. Dr Carraway is an active member of numerous professional organizations, including the American Society of Hematology.

CME Information

Applying Risk-Adapted Approaches to Management of MDS


PIM Logo PQH Logo

LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:
  • Review validated MDS classification systems and risk-stratification models
  • Discuss the treatment algorithm for low-risk MDS considering patient eligibility for allogeneic stem-cell transplantation
  • Evaluate the latest data on novel approaches to the management of low- and high-risk MDS
  • Facilitate individual treatment-goal planning by reviewing clinical outcomes of novel agents in patient subgroups
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC working in collaboration with the Aplastic Anemia and MDS International Foundation (AAMDSIF).

ACKNOWLEDGEMENT

Supported by educational grants from Bristol Myers Squibb; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; and Taiho.

TUITION

Complimentary

JointlyAccreditedProvider Logo

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ENDURING CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

Live Activity

Thursday, May 6, 2021 from 11:30am – 1:00pm ET

Enduring Material

The enduring material will be available from May 6, 2021 to May 6, 2022.

TARGET AUDIENCE

The intended audience for this activity are hematologic oncologists, hematologists, medical oncologists, BMT specialists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with MDS.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 and a half hours to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.OMedLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Mikkael A. Sekeres, MD, MS
Professor of Medicine
University of Miami
Sylvester Cancer Center
Consulting Fee (e.g. advisory boards): Bristol Myers Squibb, Novartis, Pfizer
Hetty Carraway, MD, MBA
Director, Leukemia Program
Vice Chair, Strategy and Enterprise Development
Associate Professor, Cleveland Clinic
Taussig Cancer Center
Cleveland Clinic
Consulting Fee (e.g. advisory boards): Agios, Bristol Myers Squibb, Celgene, Jazz, Novartis, Stemline
Contracted Research: Celgene
Other (DSMD/IRC): Abbvie, Astex, Takeda

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Tariqa Ackbarali
Medical Director
PlatformQ Health Education, LLC
None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Jaimee Harris-Gold, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.